Drug products: Avopenin, Fenoximetylpenicillin EQL Pharma, Kåvepenin®, Kåvepenin® Frukt, Peceve®, Primve, Tikacillin
ATC code: J01CE02
Controlled studies on differences between men and women regarding the effect, safety and pharmacokinetics of phenoxymethylpenicillin are lacking. A smaller study indicates that exposure of phenoxymethylpenicillin during pregnancy can be lower than in non-pregnant women, and dose adjustment thus can be needed.
A pharmacokinetic study described changes in phenoxymethylpenicillin pharmacokinetics during pregnancy (12 pregnant women, 6 non-pregnant controls), in comparison to non-pregnancy. Following a single dose, half-life was shorter during the third trimester compared to the non-pregnant state. Also, exposure was lower for women in the second trimester of pregnancy than for non-pregnant women. These findings indicate increased elimination of phenoxymethylpenicillin during mid and late pregnancy, although differences in elimination were non-significant. The authors recommend reduced dosing-interval or increased dose of phenoxymethylpenicillin in pregnant women .
No studies with a clinically relevant sex analysis regarding the effect of phenoxymethylpenicillin have been found.
No studies with a clinically relevant sex analysis regarding adverse effects of phenoxymethylpenicillin have been found.
Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).
Date of litterature search: 2021-01-11
Reviewed by: Diana Rydberg
Approved by: Karin Schenck-Gustafsson